For Healthcare Professionals

Questions? Call 855-4ADYNOVATE

ADYNOVATE® Proven prophylaxis +
simple, twice-weekly dosing schedule =

moments Their way

Now approved

for the treatment of hemophilia A
in children under 12 and in surgical procedures

ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] allows patients to infuse on the same 2 days every week.1

  • Efficacy

    ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] offers proven prophylaxis with a twice-weekly dosing schedule.1

    See Data
  • Dosing & Administration

    Get information about the simple, twice-weekly dosing schedule, the BAXJECT® II Hi-Flow Needleless Transfer Device, the BAXJECT III® Reconstitution System, and available dosage strengths.1

    Learn More
  • Safety

    Learn about safety findings from the ADYNOVATE clinical trial.

    See Details
  • Dedicated Support

    Shire is proud to provide a variety of programs and resources for the bleeding disorders community.

    Take Me There
  • The Science

    Learn more about the extended terminal half-life of ADYNOVATE.1

    Explore the Science

Detailed Important Risk Information
Prescribing Information (PI)
ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] Important Information
Indications

ADYNOVATE, Antihemophilic Factor (Recombinant), PEGylated, is a human antihemophilic factor indicated in children and adults with hemophilia A (congenital factor VIII deficiency) for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management
  • Routine prophylaxis to reduce the frequency of bleeding episodes

Limitation of Use

ADYNOVATE is not indicated for the treatment of von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION


Click here for ADYNOVATE full Prescribing Information.



ADVATE [Antihemophilic Factor (Recombinant)] Important Information
Indications

ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A (congenital factor VIII deficiency) for:

  • Control and prevention of bleeding episodes.
  • Perioperative management.
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

ADVATE is not indicated for the treatment of von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION


Neutralizing Antibodies

Neutralizing antibodies (inhibitors) have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs). Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration.


The most common adverse reactions observed in clinical trials (frequency >5% of subjects) were pyrexia, headache, cough, nasopharyngitis, arthralgia, vomiting, upper respiratory tract infection, limb injury, nasal congestion, and diarrhea.

Click here for ADVATE full Prescribing Information.